Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Calls For More Consistent European Oversight As EU Continues Reg Reform Process

This article was originally published in The Gray Sheet

Executive Summary

Industry says it supports a more consistent approach to medical device regulation in the EU, a goal that may be advanced by the European Commission’s stated plans to revise the Medical Device Directives in the form of regulations rather than sticking with less-stringent directives.

You may also be interested in...



EU Device Reform Proposal Adds More Government Scrutiny, But No FDA-Like Review Body

The recommendation attracting the most concern from industry: a new Medical Device Coordination Group that would have the option to scrutinize third-party pre-market assessment reports for select devices prior to marketing.

Europe Device Reg Reform Proposal: More Scrutiny Of Notified Bodies Expected

Industry expects the European Commission to propose more oversight of notified-body reviews by member countries. But the Commission appears to have resisted calls to establish a direct government approval process for devices.

Metal-On-Metal Hips Get Failing Grade In New Registry Analysis

Devices were linked to a notably higher five-year revision rate compared to metal-on-polyethylene or ceramic-on-ceramic hips in an analysis of more than 400,000 implants. Recalled J&J/DePuy ASR devices were not included in the analysis.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel